Thakkar RB - Search Results

1

Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.

Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar RB, Hibi T. Tanida S, et al. Among authors: thakkar rb. Clin Gastroenterol Hepatol. 2015 May;13(5):940-8.e3. doi: 10.1016/j.cgh.2014.08.042. Epub 2014 Sep 19. Clin Gastroenterol Hepatol. 2015. PMID: 25245624 Free article. Clinical Trial.

2

Adalimumab induces deep remission in patients with Crohn's disease.

Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Colombel JF, et al. Among authors: thakkar rb. Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5. doi: 10.1016/j.cgh.2013.06.019. Epub 2013 Jul 12. Clin Gastroenterol Hepatol. 2014. PMID: 23856361 Clinical Trial.

3

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M. Suzuki Y, et al. Among authors: thakkar rb. J Gastroenterol. 2014 Feb;49(2):283-94. doi: 10.1007/s00535-013-0922-y. Epub 2013 Dec 24. J Gastroenterol. 2014. PMID: 24363029 Free PMC article. Clinical Trial.

4

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.

Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, Hibi T. Inoue N, et al. Among authors: thakkar rb. Intest Res. 2017 Jul;15(3):395-401. doi: 10.5217/ir.2017.15.3.395. Epub 2017 Jun 12. Intest Res. 2017. PMID: 28670237 Free PMC article.

5

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R. Watanabe M, et al. J Crohns Colitis. 2014 Nov;8(11):1407-16. doi: 10.1016/j.crohns.2014.04.012. Epub 2014 May 27. J Crohns Colitis. 2014. PMID: 24874893 Clinical Trial.

6

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M. Suzuki Y, et al. J Gastroenterol. 2017 Sep;52(9):1031-1040. doi: 10.1007/s00535-017-1325-2. Epub 2017 Mar 20. J Gastroenterol. 2017. PMID: 28321512 Free PMC article. Clinical Trial.

7

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.

Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Osterman MT, et al. Among authors: thakkar rb. Gastroenterology. 2014 Apr;146(4):941-9. doi: 10.1053/j.gastro.2013.12.025. Epub 2013 Dec 18. Gastroenterology. 2014. PMID: 24361468

8

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Colombel JF, et al. Among authors: thakkar rb. Am J Gastroenterol. 2014 Nov;109(11):1771-80. doi: 10.1038/ajg.2014.242. Epub 2014 Aug 26. Am J Gastroenterol. 2014. PMID: 25155227 Free PMC article. Clinical Trial.

9

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M. Suzuki Y, et al. J Gastroenterol. 2017 Sep;52(9):1079. doi: 10.1007/s00535-017-1340-3. J Gastroenterol. 2017. PMID: 28405767 Free PMC article. No abstract available.

10

Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.

Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T. Motoya S, et al. Inflamm Intest Dis. 2018 Jul;2(4):228-235. doi: 10.1159/000486786. Epub 2018 May 15. Inflamm Intest Dis. 2018. PMID: 30221150 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters